Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Progression Independent of Relapse Activity (US/EU)
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
Gastroesophageal Cancer – Unmet Need – Unmet Need – Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (US/EU)
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
Pancreatic Cancer – Unmet Need – Unmet Need – Locally Advanced or Metastatic Pancreatic Adenocarcinoma (US/EU)
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Non-Small-Cell Lung Cancer | Unmet Need | EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC | US/EU5 | 2023
Approximately 20% of Western patients with nonsquamous NSCLC present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive…
